LACTULOSE SOLUTION USP - LIQ 667MG/ML 667 MG
LACTULOSE : 667 MG · DIN 02148056 · BDH INC.
Health Canada status: CANCELLED POST MARKET
What is LACTULOSE SOLUTION USP - LIQ 667MG/ML?
LACTULOSE SOLUTION USP - LIQ 667MG/ML 667 MG contains LACTULOSE : 667 MG. It is listed in the Health Canada Drug Product Database under DIN 02148056, held by BDH INC., supplied as LIQUID for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 11-Aug-1999. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02148056 |
|---|---|
| Brand name | LACTULOSE SOLUTION USP - LIQ 667MG/ML |
| Generic / active ingredient | LACTULOSE : 667 MG |
| Manufacturer | BDH INC. |
| Strength | 667 MG |
| Dosage form | LIQUID |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A06AD11 LACTULOSE |
| AHFS class | 56:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 11-Aug-1999 |
| Original market date | 1995-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code A06AD11 LACTULOSE. 5 of 28 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP-LACTULOSE | 667 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02295881 |
| LACTULOSE | 667 MG | SOLUTION | SANIS HEALTH INC | MARKETED | DIN 02412268 |
| PMS-LACTULOSE-PHARMA | 667 MG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02469391 |
| RATIO-LACTULOSE | 667 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 00854409 |
| TEVA-LACTULOSE | 667 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02331551 |
| CEPHULAC SYR 667MG/ML | 667 MG | SYRUP | HOECHST MARION ROUSSEL CANADA INC. | CANCELLED POST MARKET | DIN 02091925 |
| CHRONULAC SYR | 667 MG | SYRUP | MERRELL PHARMS INC., DIVISION OF MERRELL DOW (CAN) | CANCELLED POST MARKET | DIN 00534528 |
| CHRONULAC SYR 667MG/ML | 667 MG | SYRUP | HOECHST MARION ROUSSEL CANADA INC. | CANCELLED POST MARKET | DIN 02091917 |
| COMALOSE R SIROP 10GM/15ML | 10 G / 15 ML | SYRUP | ROUGIER PHARMA DIVISION OF RATIOPHARM INC | CANCELLED POST MARKET | DIN 00651796 |
| DUPHALAC | 95 G / 100 G | POWDER | SOLVAY PHARMA INC | CANCELLED POST MARKET | DIN 02231527 |
Who else supplies LACTULOSE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LACTULOSE appears in 728 registered pack listings across 7 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.